BD Plays It Safe
It's not often that a company gets the chance to, in effect, reinvent a major product category. Moreover, it's not often that government legislators and regulators give the company a significant boost in its effort. But that's exactly what's happened for sharps product leader Becton Dickinson & Co. As concerns about health care worker safety mount, legislation recently enacted in California requires hospitals to convert from severly price-squeezed conventional sharps products to new, specially-designed products--a kind of decommoditization of these highly commoditized product categories. And BD officials hope the California law is only the beginning.
You may also be interested in...
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
In a pair of guidance documents the US agency explains clearance options and its enforcement policy for sponsors of devices used to reduce contaminants in COVID-19 masks and respirators.